MULTIHANCE 529 MG
GADOBENATE DIMEGLUMINE : 529 MG · DIN 02248302 · BRACCO IMAGING CANADA
Health Canada status: MARKETED
What is MULTIHANCE?
MULTIHANCE 529 MG contains GADOBENATE DIMEGLUMINE : 529 MG. It is listed in the Health Canada Drug Product Database under DIN 02248302, held by BRACCO IMAGING CANADA, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 28-Oct-2004. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MULTIHANCE used for?
MultiHance (gadobenate dimeglumine injection) is indicated for intravenous use in adults and children 2 years of age and older as an adjunct to magnetic resonance imaging (MRI) of the Central Nervous System (brain, spine, and surrounding structures). MultiHance is indicated for use in adults for contrast-enhanced magnetic resonance angiography (MRA) where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease in patients with suspected or known vascular disease of the supra-aortic extra-cranial, renal, or peripheral arteries. MultiHance is indicated for the use in adults for contrast-enhanced MRI of the breast, for the detection of malignant lesions in patients with known or suspected breast cancer on the basis of previous mammography or ultrasound results.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02248302 |
|---|---|
| Brand name | MULTIHANCE |
| Generic / active ingredient | GADOBENATE DIMEGLUMINE : 529 MG |
| Manufacturer | BRACCO IMAGING CANADA |
| Strength | 529 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | V08CA08 GADOBENIC ACID |
| AHFS class | 36:89.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Oct-2004 |
| Original market date | 2004-10-28 00:00:00 |
How is it stored and handled?
null
How is it supplied?
5mL, 10mL, 15mL, and 20mL single-dose vials in boxes of five; 50mL and 100mL multiple-dose Pharmacy Bulk Packages
Who else supplies GADOBENIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GADOBENIC ACID appears in 7 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.